The Boulder Peptide Society is a non-profit 501(3)c organization dedicated to supporting the advancement of peptide therapeutics. The Society organizes the Annual Boulder Peptide Symposium as a key vehicle for driving the science and technology in this important field.
The Boulder Peptide Society is governed by a Board of Directors with overall responsibility for advancing the Society's mission.
The Scientific Advisory Board consists of key opinion leaders and preeminent experts drawn from both academic and industry backgrounds with expertise in peptide and protein therapeutics. The Scientific Advisory Board has the primary responsibility for organizing the scientific program for the Boulder Peptide Symposium.
All members of the leadership team serve in a purely voluntary capacity.
Christopher Rhodes, Ph.D. Contact
President and Member Board of Directors
Dr. Rhodes is a pharmaceutical technologist with experience in combination product development including pulmonary inhalation aerosol, nasal spray, transdermal patch, sustained release injection, and oral formulations for biopharmaceutical products and small molecules. Dr. Rhodes has been responsible for product development including drug delivery R&D, formulation and process development, clinical supply and manufacturing, analytical and bioanalytical chemistry in companies including Amylin Pharmaceuticals, Guilford Pharmaceuticals, and Mannkind Pharmaceuticals. Dr. Rhodes earned his Doctorate degree in physical organic chemistry from UCLA and completed his training with a Post Doctoral position at Yale University. He has a Bachelors degree in chemistry from New York University. Dr. Rhodes founded Drug Delivery Experts in 2014 after 4 years of consulting and 20 years in pharmaceutical, biotechnology, and drug delivery companies, where he held both technical and executive leadership roles. He has extensive experience translating molecular therapeutics, formulation, delivery, and device programs from late stage research into clinical development.
Yvonne Angell, Ph.D. Contact
Vice President, Chair Scientific Advisory Board and Member Board of Directors
Dr. Yvonne M. Angell is the Director and Head of Peptide Chemistry at ChemPartner, where she leads a large peptide chemistry team located in Shanghai, China as well as San Francisco, CA. She drives the peptide therapeutic design and discovery efforts on numerous projects and oversees chemistry operations. Prior to joining ChemPartner, Dr. Angell led research teams and peptide programs across various therapeutic areas at Eli Lilly, Wyeth, Affymax, and Ipsen Bioscience. Previously, she has consulted with startup companies to strategize and guide peptide programs through her consulting company, Picotide Technologies. She has advanced many drug discovery programs including five drug candidates into preclinical development, one in the market, and one in phase I clinical trials.
Dr. Angell received her PhD from the University of Wisconsin, Madison, and carried out postdoctoral peptide research as an NIH Fellow at the University of Minnesota, Minneapolis. She is as an inventor on several patents and has numerous scientific publications.
Syed Reza, Ph.D., M.D. Contact
Member Board of Directors
Syed Reza is a physician scientist with over ten years Business Development experience in pharmaceutical sciences. Syed has worked on diverse formulation development projects involving peptides, siRNA, proteins and small molecules. Syed is currently the Director of Business Development for OctoPlus N.V specializing in controlled release technologies for injectibles. From 2008 to 2011 he was the Business Development Manager for Hoffmann-LaRoche in Boulder Colorado responsible for developing the contract peptide manufacturing business. Syed has also chaired the Annual Roche Colorado Peptide Symposium since 2009. Previously he was the Process Scientist for Nova Specialty Chemicals and was responsible for scale-up and development of exothermic chemical processes for third party clients. Syed obtained his MD-PhD from University of Medicine of New Jersey in 2003 and his B.S in Chemistry from The George Washington University in 1993.
John P. Mayer, Ph.D. Contact
Research Scientist, University of Colorado, Boulder
Adam Mezo, Ph.D. Contact
Sr. Director, Head of Molecular Design, Ferring Research Institute, Inc.
Waleed Danho, Ph.D. Contact
Consultant and Former Research Leader, Hoffmann-La Roche Inc.
Michael Wagner, Ph.D. Contact
Head of Peptides & Insulins, Sanofi
Chris McGee, Ph.D. Contact
Director, Business Development, Bachem North America Inc.
Ezekiel Nims, Ph.D. Contact
Senior Scientist, Ipsen Bioscience Inc.
Lisa Caralli, Ph.D. Contact
Senior Director, Pharmaceutics, Catalent
Chengzao Sun, Ph.D. Contact
Principal Scientist, Johnson & Johnson
Mohamed Elsayed, Ph.D. Contact
Research Fellow and Scientific Leader, Eli Lilly
Marc Jacob, Ph.D. Contact
Business Development Manager, Phenomenex
Ratmir Derda, Ph.D. Contact
Founder and C.E.O., 48Hour Discovery Inc.
Dave Garman, Ph.D. Contact
Chief Technology Officer, NoNO Inc.
Lauren Goodrich, Ph.D. Contact
Anamika Singh, Ph.D. Contact
Investigator, Intarcia Therapeutics, Inc.
Kenny Yoon Contact
Southwest Regional Manager, Wyatt Technology
Rebecca Nofsinger Contact
Associate Principle Scientist, Merck
Andrew Parker Contact
Chief Scientific Officer and Executive Vice President, Zealand Pharma
Boulder Peptide Society
11494 Sorrento Valley Rd
San Diego, CA 92121
Click here to send us an email.